[{"Date":"Apr. 28, 2010 at 10:06 a.m. ET","Headline":"BioCryst rallies on gout study; indices diverge","Summary":"BOSTON (MarketWatch) -- Shares of BioCryst Pharmaceuticals  rallied early Wednesday, after the biotech group reported positive interim results from a Phase II clinical trial for its drug BCX4208 in the treatment of gout. B..."},{"Date":"Oct. 5, 2011 at 8:23 a.m. ET","Headline":"BioCryst Pharma gout treatment meets study goals","Summary":"BioCryst Pharmaceuticals Inc. BCRX said its treatment for gout in combination with a traditional medicine for the disease reached its primary endpoints in a recent study. The drug developer's shares were up 12.6% at $2.95 ..."},{"Date":"Oct. 10, 2011 at 6:21 p.m. ET","Headline":"How Wall Street scammed Mom and Pop \u2014 again","Summary":"Commentary: Investors in this year\u2019s fund IPOs should be protesting"},{"Date":"Nov. 8, 2011 at 10:42 a.m. ET","Headline":"BioCryst shares gain as new gout data's presented","Summary":"BioCryst Pharmaceuticals Inc. BCRX presented new data on its treatment for gout in combination with a traditional medicine for the disease, following a successful Phase 2b trial. The drug developer's shares rose 6.6% to $3..."},{"Date":"Feb. 15, 2012 at 12:21 p.m. ET","Headline":"BioCryst jumps on hepatitis C study","Summary":"BOSTON (MarketWatch) -- Shares of BioCryst Pharmaceuticals  jumped 13% to $4.15 on Wednesday after the biotech group unveiled positive preclinical data for their compound BCX5191 in the treatment of hepatitis C. The compou..."},{"Date":"Jun. 6, 2012 at 4:46 p.m. ET","Headline":"Wednesday\u2019s biggest gaining and declining stocks","Summary":"BOSTON (MarketWatch) -- Shares of BioCryst Pharmaceuticals  jumped 15% to $3.55 Wednesday after the biotech group said it plans to present results from a Phase II study for its drug candidate BCX4208 in the treatment of go..."},{"Date":"Jun. 6, 2012 at 1:16 p.m. ET","Headline":"BioCryst jumps ahead of study presentation","Summary":"BOSTON (MarketWatch) -- Shares of BioCryst Pharmaceuticals  jumped 15% to $3.55 Wednesday after the biotech group said it plans to present results from a Phase II study for its drug candidate BCX4208 in the treatment of go..."},{"Date":"Nov. 8, 2012 at 11:49 a.m. ET","Headline":"BioCryst halts peramivir study over poor results","Summary":"BioCryst Pharmaceuticals Inc. BCRX said an independent committee recommended the drug developer end a study of its peramivir treatment for hospitalized patients with serious cases of influenza. The company's stock was down..."},{"Date":"Dec. 7, 2012 at 7:45 a.m. ET","Headline":"BioCryst Pharma to halve workforce","Summary":"BioCryst Pharmaceuticals Inc. (BCRX) will lay off 50% of its workforce as part of a restructuring program aimed at cutting costs while advancing its antiviral program and its program for hereditary angioedema, an immune sy..."},{"Date":"Jan. 23, 2014 at 12:01 a.m. ET","Headline":"BioCryst on the Cusp of Opportunity","Summary":""},{"Date":"Oct. 3, 2014 at 4:14 p.m. ET","Headline":"Meet the drug companies fighting Ebola","Summary":""},{"Date":"Aug. 8, 2015 at 12:01 a.m. ET","Headline":"Time to Buy Commodities","Summary":""},{"Date":"May. 18, 2016 at 12:45 p.m. ET","Headline":"NYSE trading glitch hits nearly 200 securities","Summary":"A technical malfunction at the New York Stock Exchange on Wednesday resulted in the suspension of trading of about 200 securities, a NYSE spokeswoman confirmed to MarketWatch. The glitch occurred soon after the start of tr..."},{"Date":"Aug. 6, 2016 at 12:11 p.m. ET","Headline":"Watch these biotechs as the Zika virus moves to the U.S.","Summary":""},{"Date":"Mar. 14, 2017 at 9:28 a.m. ET","Headline":"It\u2019s time to vaccinate your investments against a deadly bird flu","Summary":""},{"Date":"Apr. 6, 2018 at 4:07 p.m. ET","Headline":"Activist Starboard Value Looks Into Forest City Realty","Summary":"Plus, brief descriptions of 11 of last week\u2019s SEC filings"},{"Date":"Dec. 15, 2022 at 8:52 a.m. ET","Headline":"BioCryst to discontinue development of drug","Summary":"Shares of BioCryst Pharmaceuticals Inc.  were down about 5% in premarket trading on Thursday after the company said it halted development of BCX9930, which was being tested as a treatment for paroxysmal nocturnal hemoglobi..."}]